dianabol stack

Dianabol stack hydrochloride 50 mg; auxiliary components (1 mg per tablet) : lactose – 34.975 (including losses due to excess bulk in the manufacture of – 2.93%), corn starch – 15.0, carmellose – 20.0 Acid anhydrous silicic – 4.0 magnesium stearate – 1.0 hypromellose – 4.4 macrogol 6000 – 0.4 titanium dioxide – 0.2, carnauba wax – 0.025.

 

 

Description: white round tablets, film-coated, with Valium on one party and chasing «HC 803″ on the other.

 

Pharmacotherapeutic group – GI motility stimulant – acetylcholine release stimulant.

ATC code – A03FA.

 

pharmacological properties

Mechanism of action

dianabol stack hydrochloride enhances gastrointestinal motility by antagonism of D 2 -dopaminovyh receptors and inhibition of acetylcholinesterase. dianabol stack activates acetylcholine release and inhibits its destruction.

 

pharmacodynamics

dianabol stack hydrochloride also gives an antiemetic effect by interaction with D 2 receptors located in the trigger zone. dianabol stack caused a dose-dependent inhibition of apomorphine-induced emesis.

dianabol stack hydrochloride activates the propulsive motility of the stomach due to the antagonism of D 2 receptors, and dose-dependent inhibition of acetylcholinesterase activity.

dianabol stack hydrochloride has a specific effect on upper gastrointestinal transit speeds up stomach emptying and improves it.

dianabol stack hydrochloride did not affect the levels of serum gastrin.

 

Pharmacokinetics

Suction

dianabol stack hydrochloride is rapidly and almost completely absorbed in the digestive tract. The relative bioavailability is 60%, which is associated with the metabolism of the first pass through the liver. Food does not affect the bioavailability. The maximum plasma concentration (C max ) of 0.28 mcg / ml is reached in 0.5-0.75 hours after administration of 50 mg dianabol stack hydrochloride.

Repeated dose dianabol stack hydrochloride orally at a dose of 50-200 mg tid for 7 days pharmacokinetics and its metabolites was linear and was minimal accumulation.

Distribution

dianabol stack hydrochloride 96% bound to plasma proteins, mainly albumin. Binding to alpha 1-acid glycoprotein is less than 15% of total binding.

dianabol stack actively distributed in tissues (volume of distribution of 6.1 l / kg) and is found in high concentrations in the kidneys, small intestine, liver, adrenal gland and stomach. Penetration into the brain and spinal cord minimum. dianabol stack passes into breast milk.

Metabolism

dianabol stack active undergoes biotransformation in the liver in humans. 3 the metabolite identified, only one of which exhibits low activity, which is not a pharmacological value (about 2-3% of that dianabol stack). The primary metabolite in humans is N-oxide, which is formed by the oxidation of quaternary amino-N-dimethyl group.

dianabol stack metabolized by the action of flavin-dependent monooxygenase (FMO3). The amount and efficacy in humans FMO isozymes may differ depending on the genetic polymorphisms which rarely leads to the development of an autosomal recessive condition known as Trimethylaminuria (syndrome “fish odor”). Patients with Trimethylaminuria elimination half dianabol stack increases.

According to pharmacokinetic studies in vivo, dianabol stack not inducing or inhibitory effect on CYP2C19 and CYP2E1. dianabol stack therapy does not affect the activity or uridindifosfatglyukuroniziltransferazy CYP.

breeding

dianabol stack hydrochloride and its metabolites are excreted mainly in urine. Renal excretion dianabol stack and its N-oxide after a single oral administration of the drug at therapeutic doses in healthy individuals was 3.7 and 75.4%, respectively. The terminal elimination half dianabol stack hydrochloride is equal to about 6 hours.

 

Indications

dianabol stack hydrochloride is used for the symptomatic treatment of functional dyspepsia, nonulcer (chronic gastritis), particularly relief of bloating, early satiety, pain or discomfort in the upper abdomen, anorexia, heartburn, nausea and vomiting.

 

Contraindications

• Hypersensitivity to dianabol stack or any subsidiary component of the drug;

• patients with gastrointestinal bleeding, mechanical obstruction or perforation;

• children’s age (16 years);

• pregnancy and lactation.

 

Used with caution

Due to increased dianabol stack action of acetylcholine, should be used with caution because of the possible development of cholinergic adverse reactions in the category of patients for whom their appearance may worsen for the underlying disease.

 

Use during pregnancy and lactation

Ganaton Use during pregnancy and lactation is recommended only in cases when there is no safer alternative, and the expected benefit outweighs the potential risk.

 

DOSAGE AND ADMINISTRATION

Typically, an adult appointed interior Ganaton 1 tablet of 50 mg 3 times a day before meals. The recommended daily dose is 150 mg. This dose may be reduced considering the patient’s age.

 

Side effect

From the blood and lymphatic system: leukopenia, thrombocytopenia.

 

Allergic reactions: skin redness, itching, rash, anaphylaxis.

 

Endocrine disorders: increase in prolactin, gynecomastia.

 

From the nervous system: dizziness, headache, tremor.

 

On the part of the digestive tract: diarrhea, constipation, abdominal pain, excessive salivation, nausea, jaundice.

 

Changes in laboratory parameters: increase in aspartate aminotransferase activity (the ACT), alanine aminotransferase (ALT), gammaglyutamiltranspeptidazy, alkaline phosphatase and bilirubin.

 

OVERDOSE

Cases of overdose have not been described in humans. In case of overdose shows gastric lavage and symptomatic therapy.

 

INTERACTION WITH OTHER DRUGS

Metabolic interaction is hardly possible, as dianabol stack metabolized by the action of the flavin monooxygenase and not CYP450.

With simultaneous use of warfarin, diazepam, diclofenac sodium, ticlopidine hydrochloride, nifedipine and nicardipine hydrochloride changes in protein binding was observed.

dianabol stack enhances gastric motility, so it can affect the absorption of other drugs that are prescribed inside. Particular caution should be observed in the use of drugs with a low therapeutic index, as well as forms with sustained release of the active substances or preparations with an enteric coating.

Anti-ulcer drugs such as cimetidine, ranitidine, and teprenone cetraxate not affect the prokinetic effect dianabol stack.

Anticholinergic agents may impair the effect dianabol stack.

release Form

Film-coated tablets, 50 mg.

At 7, 10 or 14 tablets in a blister made of PVC / AL-foil. 1, 2, 3, 4 or 5 blisters with instructions for use in a carton box. alphabolin